Saba Malak
Saba Malak’s career has spanned strategic consulting, public equity investments, and leadership and operation of startups. He has deep experience in healthcare and technology companies.
Most recently, Mr. Malak was Chief Executive Officer of Zahav Bioscience, a clinical stage oncology company established by a large family office to develop Cytimmune Sciences’ therapeutics assets. He previously served as CEO and Chairman of Cytimmune Sciences; a novel oncology platform company he helped turned around after assuming leadership from its founder/CEO.
Mr. Malak started his career in management and strategy consulting, serving as Principal of the Boston Consulting Group where he advised pharmaceutical, healthcare, telecom, and technology clients. He subsequently served as Managing Director at Putnam Investments where he invested in the largest global technology companies. His roles at Putnam included analyst, technology team leader, and technology portfolio manager.
Mr. Malak has broad experience as an angel investor in early-stage healthcare companies, with two successful exits to date. He was previously a Director of Advanced Practice Strategies, a SaaS medical risk and human capital management (HCM) company sold to Relias Learning (subsidiary of Bertelsmann). In digital health, he was an investor in Wellframe, which was sold to Healthedge (Blackstone). He has also made investments in medical technology and synthetic biology companies.
He received a Bachelor of Science in Electrical Engineering, summa cum laude, from Tufts University where he was elected and was President of Tau Beta Pi. He was also awarded an MSE in Systems Engineering from the University of Pennsylvania, and an MBA from Harvard Business School.
